Avadel Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its supplemental new drug application for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. LUMRYZ is a once-at-bedtime formulation extended-release sodium oxybate and was first approved by the FDA on May 1, 2023, for the treatment of cataplexy or EDS in adult patients with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population 7 years and older on October 16, 2024, and was granted Orphan Drug Exclusivity through October 16, 2031.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals call volume above normal and directionally bullish
- Avadel Pharmaceuticals announces publication of data on LUMRYZ
- Avadel Pharmaceuticals Advances Pediatric Narcolepsy Treatment Review
- Avadel publishes RESTORE data on LUMRYZ for narcolepsy patients
- H.C. Wainwright says buy Avadel selloff, court ruling ‘unequivocal win’